Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

Despite proven benefits, prophylactic treatment for hemophilia A is hampered by the short half-life of factor VIII. A recombinant factor VIII-Fc fusion protein (rFVIIIFc) was constructed to determine the potential for reduced frequency of dosing. rFVIIIFc has an ∼ 2-fold longer half-life than rFVIII...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Dumont, Jennifer A., Liu, Tongyao, Low, Susan C., Zhang, Xin, Kamphaus, George, Sakorafas, Paul, Fraley, Cara, Drager, Douglas, Reidy, Thomas, McCue, Justin, Franck, Helen W. G., Merricks, Elizabeth P., Nichols, Timothy C., Bitonti, Alan J., Pierce, Glenn F., Jiang, Haiyan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2012
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3953019/
https://ncbi.nlm.nih.gov/pubmed/22246033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-08-367813
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller